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ABSTRACT
Objectives: To explore differences in mean costs
(from a UK National Health Service perspective) and
effects of pharmacist-led management of chronic pain
in primary care evaluated in a pilot randomised
controlled trial (RCT), and to estimate optimal sample
size for a definitive RCT.
Design: Regression analysis of costs and effects,
using intention-to-treat and expected value of sample
information analysis (EVSI).
Setting: Six general practices: Grampian (3); East
Anglia (3).
Participants: 125 patients with complete resource
use and short form-six-dimension questionnaire
(SF-6D) data at baseline, 3 months and 6 months.
Interventions: Patients were randomised to either
pharmacist medication review with face-to-face
pharmacist prescribing or pharmacist medication
review with feedback to general practitioner or
treatment as usual (TAU).
Main outcome measures: Differences in mean total
costs and effects measured as quality-adjusted life
years (QALYs) at 6 months and EVSI for sample size
calculation.
Results: Unadjusted total mean costs per patient were
£452 for prescribing (SD: £466), £570 for review (SD:
£527) and £668 for TAU (SD: £1333). After controlling
for baseline costs, the adjusted mean cost differences
per patient relative to TAU were £77 for prescribing
(95% CI −82 to 237) and £54 for review (95% CI
−103 to 212). Unadjusted mean QALYs were 0.3213
for prescribing (SD: 0.0659), 0.3161 for review (SD:
0.0684) and 0.3079 for TAU (SD: 0.0606). Relative to
TAU, the adjusted mean differences were 0.0069 for
prescribing (95% CI −0.0091 to 0.0229) and 0.0097
for review (95% CI −0.0054 to 0.0248). The EVSI
suggested the optimal future trial size was between
460 and 690, and between 540 and 780 patients per
arm using a threshold of £30 000 and £20 000 per
QALY gained, respectively.
Conclusions: Compared with TAU, pharmacist-led
interventions for chronic pain appear more costly
and provide similar QALYs. However, these estimates
are imprecise due to the small size of the pilot trial.
The EVSI indicates that a larger trial is necessary
to obtain more precise estimates of differences in
mean effects and costs between treatment groups.
Trial registration number: ISRCTN06131530.
INTRODUCTION
Chronic pain is recognised as a common and
long-term condition having a signiﬁcant
impact on the quality of life of individuals
and their families, along with a considerable
ﬁnancial cost to society. Its pathophysiology
and psychosocial impact are largely
independent of its biological aetiology and
therefore, comprehensive approaches to
identifying, designing and targeting relevant
interventions have been advocated, whereby
chronic pain is dealt with as a whole clinical
entity, regardless of its underlying cause.1
Chronic pain is characterised by pain which
persists despite adequate time for healing.
Although there is no clear deﬁnition, it is
often deﬁned as pain that has been present
for more than 3 months.2 Approximately 20%
of the European adult population have
chronic pain3 and the economic burden is
Strengths and limitations of this study
▪ This is the first study to assess the differences in
costs and effects (in terms of quality-adjusted
life years (QALYs)) associated with pharmacist
prescribing and/or pharmacist review compared
with treatment as usual (TAU) in the manage-
ment of chronic pain in primary care.
▪ The results are imprecise as they were based on
a pilot randomised controlled trial and a larger
trial based on these results is now needed.
▪ Using a value of information approach to deter-
mine optimal sample, findings suggest a future
trial requires between 460 and 690, and between
540 and 780 patients per arm using a threshold
of £30 000 and £20 000 per QALY gained,
respectively, in order to obtain more precise esti-
mates of differences in mean QALYs and mean
costs between treatment groups.
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considerable with national healthcare and socioeconomic
costs running into billions annually, representing
between 3% and 10% of European gross domestic
product (GDP)4 and from $560 to $635 billion annually
in the USA.5 In the UK, an estimated 11%6 of adults
suffer from severe chronic pain, representing around 4.5
million people. The average annual incidence risk esti-
mated from health surveys of developing chronic pain is
8.3% and for those already with chronic pain (ie, preva-
lent cases), the average annual recovery rate is 5.4%.7
The total cost of back pain alone has been estimated to
be £12.3 billion annually in the UK or 1.5% of GDP.8
The majority of patients with chronic pain are
managed outside the specialist setting, mainly in primary
care; however, patients will make a variety of choices for
self-management of their pain.3 Pharmacological and
non-pharmacological management options exist with
provision of the former involving mostly primary care or
purchase of over-the-counter medicines from the com-
munity pharmacy or supermarket; the latter options
include cognitive behavioural therapy, physiotherapy or
alternative therapies and are often provided privately.
The recent Scottish Intercollegiate Guidelines Network
(SIGN) guideline on chronic pain1 reviewed the evi-
dence for assessment and management of chronic non-
malignant pain in the adult population in the non-
specialist setting and reported on the current lack of
good quality evidence to guide management. The guide-
line indicated a range of recommendations relating to
pharmacological therapies including, for example, the
provision of at least an annual assessment of patients on
pharmacotherapy for chronic pain.
We recently reported ﬁndings from the ‘Pharmacist-
led management of chronic pain in primary care’
(PIPPC) pilot trial in which pharmacist medication
review with face-to-face pharmacist prescribing was com-
pared with pharmacist medication review with feedback
to the general practitioner (GP) or usual GP-led care.9
This was the ﬁrst pilot randomised controlled trial
(RCT) to compare key clinical outcomes (rather than
process end points) between pharmacist-led interven-
tions for adults with chronic pain with the usual GP
care. Although it was a pilot trial to inform the design
for a subsequent deﬁnitive trial, the ﬁndings suggested
that compared to usual care, participants’ pain levels, as
measured by the chronic pain grade (CPG), improved
in both pharmacist-led intervention groups, particularly
in the group managed by pharmacist prescribing. The
pilot trial also collected data on resource use and
health-related quality of life. This provided an opportun-
ity to assess the impact of pharmacist-led interventions
on health economic outcomes and to offer some insight
into the potential value for money of the study interven-
tions. The objective of this paper, therefore, is to calcu-
late the differences in mean costs and effects of the
interventions, and the precision of those estimates so as
to inform sample size and other design considerations
for a future deﬁnitive trial.
METHODS
Overview of the PIPPC trial
The PIPPC study9 was a UK-based 6-month open explora-
tory pilot RCT primarily designed to investigate the
effectiveness of either pharmacist medication review and
face-to-face pharmacist prescribing, or pharmacist medi-
cation review and feedback to GP, relative to treatment as
usual (usual GP-led care). The study was performed in
six general practices with an attached independent
pharmacist prescriber (3 in Grampian and 3 in East
Anglia). Full details have been reported previously.9
Brieﬂy, a total of 196 patients were recruited into the trial
between March and June 2010. Included patients were:
over 18 years of age; living in their own home; and receiv-
ing regular prescribed medication for pain (deﬁned as
receiving within the previous 120 days either two or more
acute prescriptions, and/or one repeat prescription for
an analgesic and /or a non-steroidal anti-inﬂammatory
drug (NSAID)). Patients were randomised in a 1:1:1 ratio
to receive either pharmacist medication review with
pharmacist prescribing (n=70) or pharmacist review only
(n=63) or TAU (n=63). Patients and their healthcare pro-
viders were unblinded due to the nature of the interven-
tion. Trial outcomes assessed by self-report in postal
questionnaires at baseline, and at 3 and 6 months’
follow-up included: the short form mental (SF-12 MCS)
and physical (SF-12 PCS) component summary scores,
the generic preference-based health state utilities
measure short form-six-dimension questionnaire
(SF-6D), the CPG, and the Hospital Anxiety and
Depression Scale (HADS). Preference weights (utilities)
for the SF-6D health status measure were derived using
the recommended tariffs derived from a UK general
population survey.10 Data on health service resource use
were also collected at three time points: baseline (to
measure service use 3 months prerandomisation),
3 months (to measure resource use 3 months postrando-
misation) and 6 months (to measure resource use
3–6 months postrandomisation), as described below.9
Resource use and unit costs
The economic analysis included the direct costs asso-
ciated with the intervention (pharmacist training,
pharmacist and GP time involved in delivering the inter-
vention along with related follow-up), pain-related hospi-
talisation (number of hospital inpatient days, day cases
and outpatient visits), primary care visits for chronic pain
(GP, nurse, healthcare assistant appointments), primary
care telephone contacts for chronic pain, prescribed and
non-prescribed OTC pain-related medications.
Frequency of the above primary and secondary care
visits, and names and quantity of medicine prescribed
were measured and valued using information from
patients’ medical records and by patient self-reported
questionnaire. Standard unit costs from published UK
sources were attached to these items of resource use.
Resource use quantities and the assigned unit costs used
in this analysis are summarised in table 1. For study
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medications, unit costs were obtained from the British
National Formulary.11 Hospital inpatient and outpatient
unit costs were based on average costs from the Scottish
Health Service Costs Book.12 Intervention-related
pharmacist and GP time were based on costs from the
Personal Social Services Research Unit (PSSRU).13
Intervention-related costs (pharmacist training, etc.)
was based on information obtained from follow-up semi-
structured interviews with pharmacists and GPs in par-
ticipating practices.
Other costs borne by patients (eg, OTC medicines,
travel) or their carers, and productivity losses to society
Table 1 Unit costs applied to NHS resource use in the PIPPC study
Resource use item Value (£) Unit Source/comments
Intervention costs
Pharmacist training Prescribing:
£10.85
Review: £10.67
Per patient PSSRU 2009/201013 2 days (ie16 h) @ £40/h
(includes travel)=£40×16=£640, this cost being
apportioned over the number of patients in each
intervention group
Intervention delivery Prescribing:
£66.7
Review: £44
Per patient PSSRU 2009/201013 £40/h (includes travel)
Prescribing: mean duration 100 min; Review: mean
duration 66 min
Pharmacist follow-up
appointments
Prescribing:
£6.18
Review: £0
Per patient PSSRU 2009/201013 £40/h
Prescribing: 45/53 (84.9%) patients received
follow-up appointments: 0 (15.1%); 1 (62.3%)
mean duration 11 min; 2 (15.1%) mean duration
10 min, 3 (7.5%) mean duration 12 min. Most were
conducted by phone. Weighted average cost=
£6.18
Review: no follow-up appointments
GP review £45.9 Per patient PSSRU 2009/201013 £106/h of GMS activity.
Mean duration 26 min
Primary care costs
GP-home £108 Per consultation PSSRU 2009/201013
GP-surgery £32 Per consultation PSSRU 2009/201013
GP-telephone £20 Per consultation PSSRU 2009/201013
Nurse-home £20 Per consultation PSSRU 2009/201013
Nurse-surgery £12 Per consultation PSSRU 2009/201013
Nurse-telephone £7.50 Per consultation PSSRU 2009/201013 (based on an assumed
multiplier for telephone consultations for nurse and
healthcare assistant of 0.625, that is, 20/32
Other-home £9 Per consultation PSSRU 2009/201013 (clinical support worker
nursing—community)
Healthcare
assistant-surgery
consultation
£7.50 Per consultation Based on an assumed multiplier for telephone
consultations for nurse and healthcare assistant of
0.625, that is, 20/32
Hospital costs
Inpatient stay Orthopaedics=
£873
General
medicine=£395
Per bed day ISD Scotland, Scottish Health Service Costs, NHS
Grampian, year ended 31 March 201012
R040 (&LS)—Specialty Group Costs—Inpatients
Day case Pain relief=£541 (Net) per case ISD Scotland, Scottish Health Service Costs, NHS
Grampian, year ended 31 March 201012 R042—
Specialty Costs—Day Cases
Outpatient clinic—
consultant led
Pain relief=£122 Per attendance ISD Scotland, Scottish Health Service Costs, NHS
Grampian, year ended 31 March 201012 R044—
Specialty Costs—Consultant Outpatient Clinics
Outpatient clinic—other
(eg, physiotherapist)
Pain relief=£37 Per attendance ISD Scotland, Scottish Health Service Costs, NHS
Grampian, year ended 31 March 201012 R046—
Specialty Costs—AHP Outpatient Clinics
Medications Varied by
medication
Dose, duration, pack
size, number supplied
etc
BNF 61, March 201111
PIPPC study, Pharmacist-led management of chronic pain in primary care; PSSRU, Personal Social Services Research Unit; NHS National
Health Service.
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were considered outside the scope of the National
Health Service (NHS) perspective of the present ana-
lysis. All costs were in UK pounds sterling (£), undis-
counted (as the duration of the trial was less than
1 year). The price year used for all costs was 2009/2011.
Effects
The effects of the pharmacist-led interventions were esti-
mated as gain in quality-adjusted life years (QALYs).
Based on the SF-6D data collected at baseline, 3-month
and 6-month follow-up, the number of QALYs over
6 months follow-up associated with each study arm were
approximated by applying the area under the curve
(AUC) method (implemented by summing the areas of
the geometrical shapes obtained by linearly interpolat-
ing between utility scores over the study period).10
QALYs were undiscounted due to the short duration of
the trial.
Methods used to estimate differences in mean costs and
effects
Similar to the main analysis of clinical outcomes,9 the
economic analysis was conducted on an intention-
to-treat basis for participants with complete SF-6D data
at baseline, 3-month and 6-month follow-up. While
resource use information was available for 178 patients,
only 125 patients had complete SF-6D data for all three
study assessment time-points. These 125 patients formed
the sample for the main analysis. Using the data
described above, estimates of the total mean costs and
total mean QALYs per group were calculated. Regression
analyses calculated the differences (and associated 95%
CIs) in mean total costs and differences in mean total
QALYs per patient, while controlling for differences in
total costs at baseline, baseline SF-6D14 and other base-
line patient characteristics (age, sex, marital status, work
status, education, income, baseline CPG—intensity).
Sensitivity analyses
We performed a number of sensitivity analyses to
explore areas of uncertainty in the main analysis. First,
as noted above approximately one-third of patients were
excluded due to missing some SF-6D data at follow-up
(no missing cost data was apparent and so imputation
was not necessary). To assess whether this introduced
bias, we performed a sensitivity analysis with imputed
values for missing SF-6D data and re-ran the regression
analysis using data from all 178 patients. The missing
SF-6D data were imputed by multiple imputation via
chained equations with the STATA 13 ‘mi impute’
command programme to account for patients with
missing data at either 3 or 6 months assuming that data
were missing at random (and creating ﬁve imputed data
sets).15 16 Second, to investigate the impact on differen-
tial costs from patients who experienced very high costs
from the analysis, we conducted an analysis excluding
hospital inpatient costs, on the basis that some of these
costs may not be directly related to chronic pain. Finally,
we explored whether the main results were affected by
controlling only for baseline differences between groups
in total costs and SF-6D (ie, excluding sociodemographic
and economic factors, and other health status measures,
ie, the CPG).
EVSI analysis
The expected value of sample information (EVSI)17 18
was calculated to assess whether conducting a larger
RCT of pharmacist prescribing versus TAU, or pharma-
cist review versus TAU would be worthwhile. This
approach determines the optimal sample size that maxi-
mises the difference between the expected total cost
(Total Cost) of a future trial and the monetary value of
the information that it provides (EVSI). The EVSI is the
anticipated value of the health gain (or the expected
net beneﬁt of sample information (‘Expected Net Gain’,
ENG)) over the period of t years, the chosen time
horizon used for the analysis. This time horizon repre-
sents how long we expect the ‘new intervention(s)’ to
become established as the ‘standard of care in the UK’
should it be shown to be cost effective. Total Cost is cate-
gorised into three main elements: a ﬁxed component to
represent the human (ie, labour/staff resource use) and
other resources associated with the setting up and
running of the trial; a variable component to reﬂect per
patient accrual (ie, per additional patient recruited or
increases in each participant taking part and who might
potentially beneﬁt from the intervention), follow-up and
data collection costs; and an opportunity cost—health
loss to participants randomised to the control group
(assuming the intervention is effective). To generate
EVSI estimates, the difference in effectiveness, costs and
associated variances and covariances observed within the
PIPPC trial were used. In addition, assumptions were
made regarding trial ﬁxed costs, variable costs and the
number of future patients with chronic pain expected to
beneﬁt from the proposed pharmacist prescribing and
review intervention. For our analysis, we made the fol-
lowing assumptions: time horizon=30 years; annual inci-
dence=540 000 (this value was calculated based on the
average annual incidence of chronic pain is 8.3% in
adults aged 25 years and older,7 and the number of
adult population is around 42 million (last UK census)
that gives 3.5 million. This implies that approximately
1.2 million (1/3×3.5 million) people develop chronic
pain that is ongoing/long-standing (ie lasting
>3months). On the basis of the PIPPC trial,9 only a pro-
portion of these people were receiving medication—we
calculate this to be 1492 people from a total of 3281 or
45%. So, the assumed incidence used 540 000); a ﬁxed
trial cost=£1.4 million; and a variable trial cost=£220. We
generated EVSI estimates using a willingness to pay per
QALY gained of £20 000 and £30 000, respectively.
Additional sensitivity analyses checked whether the
EVSI results were robust to variations in the main ana-
lysis assumptions, including the underlying incidence
rate, the number of patients who would beneﬁt and the
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recruitment cost per patient to a trial. Speciﬁcally, we
halved and doubled the values used in the main analysis
in each alternative case, with the exception of time
horizon (10/20 years).
RESULTS
Resource use and costs
Table 2 presents the number of patients using each type
of resource (and percentages), and per patient mean
quantities used, mean unadjusted cost per type of
resource, unadjusted total mean costs and the adjusted
cost differences by trial arm, from baseline to 6-month
follow-up. As the table shows, there was some variation
in the resources used and associated costs between
patients in each study arm. For example, the results
suggest that GP resource use is higher in the review
group relative to either prescribing or TAU groups, and
also that nurse practice consultations by phone is higher
in the prescribing group relative to review and TAU.
The bar charts in ﬁgure 1 show per patient the differ-
ent cost components as a proportion of the total
(unadjusted) costs in each study arm. At both baseline
and follow-up, medications accounted for the largest
percentage of the total cost in all study arms (prescrib-
ing 37%, review 31%, TAU 55%), outpatient hospitalisa-
tions for TAU (19%), intervention-related costs for
pharmacist prescribing (18%) and primary care costs,
excluding pharmacist visit costs, for pharmacist review
only (20%). Both pharmacist-led intervention arms were
less costly than TAU based on the raw unadjusted mean
total costs. The TAU group, however, was also the most
costly treatment group observed prerandomisation and
this was largely driven by medication costs; this suggests
potential imbalances between study arms at baseline
(ﬁgure 1). Following adjustment for differences in base-
line costs and controlling for other baseline patient
characteristics (age, sex, marital status, work status, edu-
cation, income, baseline CPG—intensity and baseline
SF-6D) yielded positive incremental mean costs differ-
ences for both pharmacist-led interventions relative to
TAU: prescribing £77.5 (95% CI −£81.7 to £236.7) and
review £54.4 (95% CI −£103.3 to £212.1). In other
words, the review and prescribing groups relative to TAU
were now more expensive rather than cheaper, relative
to usual care. Adjusting for baseline costs were largely
responsible for this resulting change which was statistic-
ally signiﬁcant (with a regression coefﬁcient p=0.0000).
No other variables reached signiﬁcance.
Quality-adjusted life years
Table 3 shows the SF-6D health utility scores by study arm.
The values were broadly similar across all arms at each
time point, although pharmacist prescribing showed
slightly higher SF-6D scores at all three time points.
Both pharmacist-led intervention arms generated
slightly more QALYs than TAU based on the raw
unadjusted mean total QALYs, but the magnitude of
QALY gains relative to TAU were small (approximately
0.01 extra QALYs) in both cases.
After adjusting for baseline SF-6D score, baseline costs
and controlling for other baseline patient characteristics
(age, sex, marital status, work status, education, income,
baseline CPG—intensity), QALY gains relative to TAU
were largely unchanged for pharmacist prescribing
0.0069 (−0.0091 to 0.0229) and pharmacist review
0.0097 (−0.0054 to 0.0248).
Sensitivity analyses
The sensitivity analysis with missing SF-6D data imputed
(ie, 125 out of 178 complete; 53 incomplete, so imputed)
by using multiple imputations (MI) produced similar
values to the main analyses for estimated difference in
mean total QALYs; however, differences in QALYs were
slightly larger for pharmacist prescribing versus TAU
0.0065 (−0.0075 to 0.0205) than pharmacist review versus
TAU 0.0047 (−0.0086 to 0.0181). Using the full resource
use data set and rerunning the cost regression analysis
showed the two pharmacist-led interventions still to be
more costly than TAU, though the magnitude of the
adjusted difference in cost was reduced in the prescribing
group and increased in the review group relative to TAU,
prescribing £21 (−124 to £167) and review £75 (−72 to
£221). Excluding from the total costs the few patients in
each arm having hospital inpatient care (hospital stay
and day cases) reduced raw unadjusted mean total costs
per patient by around £90, £130 and £40 in the pharma-
cist prescribing, pharmacist review and TAU arms,
respectively. The adjusted differences in mean total costs
(after controlling for baseline: costs, SF-6D, age, sex,
marital status, work status, education, income and CPG—
intensity) were increased for both pharmacist-led inter-
vention groups relative to TAU: prescribing £112 (£24 to
£200) and review £88 (−8 to £185). Controlling only for
baseline costs and baseline SF-6D (ie, excluding age, sex,
marital status, work status, education, income, baseline
CPG—intensity) in regression analyses increased incre-
mental costs for both pharmacist-led interventions rela-
tive to TAU: prescribing £125 (£82 to £242) and review
£76 (−£40 to £192); this, however, had little impact on
QALY gains relative to TAU: prescribing 0.0017 (−0.0127
to 0.0160) and review 0.0040 (−0.0099 to 0.0179)
Expected value of sample information analysis
The EVSI investigated the cost-effectiveness of carrying
out a larger RCT of pharmacist prescribing and pharma-
cist review versus TAU. The parameters used in the EVSI
calculation and the resulting expected EVSI is given in
ﬁgure 2, which also shows the expected costs of the RCT
and the resultant ENG. The expected costs of running
the proposed trial rise linearly as the sample size (n) is
increased; however, the expected beneﬁts diminish as the
sample size increases after a certain point, giving the
optimal number of patients in each arm of the RCT. The
‘optimal trial size’ (SS) is estimated as 780 per arm (pre-
scribing vs TAU comparison) and 540 per arm (review vs
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TAU comparison) using a cost per QALY threshold of
£20 000 and 690 per arm (prescribing vs TAU compari-
son), and 460 per arm (review vs TAU comparison) using
a cost per QALY threshold of £30 000.
The results of the sensitivity analyses around the main
EVSI results (see table 4) showed that this ﬁnding was
generally robust to assumptions about annual incidence
and recruitment cost, but sensitive to annual accrual
and the time horizon used.
DISCUSSION
This current study estimated the differences in mean
costs and mean effectiveness (in terms of QALYs) of
pharmacist medication review with or without prescrib-
ing as compared with usual GP care for the treatment of
chronic pain in primary care based on data from the
PIPPC pilot trial.9 We also assessed the EVSI for a deﬁni-
tive trial. The results suggested that the pharmacist inter-
ventions were likely to be more costly than TAU when
differences in costs at baseline were taken into account,
but there was a large degree of uncertainty surrounding
the estimates of differences in mean costs and mean
effects (ie, QALYs). Given this uncertainty, the economic
case for pharmacist prescribing with or without review
over TAU can only be established with a larger RCT.
The potential gain from a future trial was estimated by
the EVSI; this showed that the gains in monetary terms
from a future trial exceed the expected costs.
In the main clinical paper,9 the CPG was shown to
have potential to be able to discriminate between
patients who improved postintervention and suggested
maximum beneﬁt for those in the pharmacist prescrib-
ing arm (effect size of 0.45).9 However, the difference in
effect observed with the CPG was not reﬂected in a
(large) effect difference in terms of QALYS. We believe
a larger trial is now warranted to determine more pre-
cisely the true effects of pharmacist medication review
with or without prescribing, measured in terms of CPG
and QALYs.
To the best of our knowledge, no other published
studies have assessed the costs and effects (in terms of
QALYs) of pharmacist interventions for chronic pain or
pharmacist independent prescribing for any condition.
A small feasibility study19 examining the impact of intro-
duction of a combined nurse/pharmacist-led clinic for
managing chronic pain in primary care was reported to
lead to improvements in management of pain, as well as
a reduction in use of secondary care resources and high
rates of satisfaction. Stewart et al20 have argued for more
research into the clinical, economic and humanistic
effects of different forms of ‘non-medical prescribing’
(NMP). NMP involves the prescribing of medicines by
healthcare professionals (who are not doctors, eg,
nurses, pharmacists) but who have undergone appropri-
ate training (including pharmacovigilance) and are,
therefore, qualiﬁed to prescribe either in a supplemen-
tary or independent role within their areas of compe-
tence.20 Our study results provide new information
about the costs and QALY effects of pharmacist medica-
tion review with or without prescribing for chronic pain.
One important aspect of the design of the cost effect-
iveness component of RCTs—including those evaluating
pharmacist interventions for pain—relates to the selec-
tion of the most appropriate health utility measures.
The SF-6D was used in the current trial. An alternative is
the EQ-5D and this has become the instrument of
choice for many agencies including the National
Institute for Health and Care (formerly ‘Clinical’)
Excellence (NICE).21 The SF-6D cannot easily be com-
pared with the EQ-5D because of differences in their
descriptive systems, values applied to health states and
Figure 1 Proportion of unadjusted total mean costs per
patient prerandomisation (ie baseline) and at 6 months
follow-up, by each main cost component and study arm.
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contextual basis (ie, recall period). Moreover, a number
of studies have reported that these two measures cannot
be used interchangeably in patients with chronic
pain.22–27 In a study of 389 patients with chronic knee
pain, Barton et al28 reported that, in contrast to the
EQ-5D, the SF-6D was unable to discriminate between
patients who improved postintervention and those who
did not; but in another study of patients with chronic
low back pain and degenerative disc disease,25 the SF-6D
had the best ability to detect changes and correctly iden-
tify patients as improved or non-improved. In a UK
general population study,29 both measures were shown
to discriminate between those self-reporting chronic
pain or no chronic pain with and without neuropathic
characteristics. However, both measures generated
widely different health utility scores for the same patient
groups, for example, the mean utilities for severe pain
(EQ-5D 0.33 vs SF-6D 0.58). In another study,30 the
EQ-5D was found to be more responsive to deterioration
in health, whereas the SF-6D was more responsive to
improvement in health in patients with knee pain due
to inﬂammatory arthritis. The choice of instrument
might have a considerable impact on the conclusions
reached about the cost-effectiveness of the interventions
being evaluated. For instance, a Norwegian cost-
effectiveness study of total disc replacement versus
Table 3 SF-6D health utility scores and QALYs over 6 months follow-up in the PIPPC study (complete case analysis n=125)
Prescribing (n=39) Review (n=44) TAU (n=42)
SF-6D at baseline, mean (SD) 0.6349 (0.1336) 0.6173 (0.1431) 0.6077 (0.1140)
SF-6D at 3 months, mean (SD) 0.6428 (0.1396) 0.6411 (0.1469) 0.6226 (0.1405)
SF-6D at 6 months, mean (SD) 0.6500 (0.1462) 0.6291 (0.1471) 0.6105 (0.1336)
Unadjusted total QALYs, mean (SD) 0.3213 (0.0659) 0.3161 (0.0684) 0.3079 (0.0606)
Adjusted difference in total QALYs versus TAU,
mean (95% CI)*
0.0069 (−0.0091 to 0.0229) 0.0097 (−0.0054 to 0.0248)
The number of patients with data on all these baseline variables: prescribing (n=35); review (n=39), TAU (n=34).
*Estimates from regression analyses with adjustment for differences in baseline costs, baseline SF-6D health utility score and other patient
characteristics (age, sex, marital status, work status, education, income, baseline CPG—intensity).
QALYs, quality-adjusted life years; SF-6D, short form six-dimension; TAU, treatment as usual.
Figure 2 Value of expected value of sample information (EVSI) analysis. The expected net benefit of sampling at specified
randomised controlled trial (RCT) sizes using a threshold of £20 000 per quality-adjusted life years (QALY) gained for
(A) Prescribing versus treatment as usual (TAU), (C) Review versus TAU and using a threshold of £30 000 per QALY gained for
(B) Prescribing versus TAU and (D) Review versus TAU. From regression analysis with adjustment for baseline costs, baseline
short form six-dimension (SF-6D), and other patient characteristics (including age, sex, material status, education, work status,
income chronic pain grade (CPG)-intensity). The number of participants with data on all these baseline variables: prescribing
(n=35), review (n=39), TAU (n=34). ENG, expected net gain; EVSI, expected value of sample information; n, number of patients
in each arm; SS, sample size.
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multidisciplinary rehabilitation in patients with chronic
low back pain found that total disc replacement was cost-
effective when EQ-5D was used, but not when SF-6D was
used.26 Additionally, the practical issue of instrument
completion is important in future trial design. In our
analysis, we found around one-third of SF-6D measure-
ments were incomplete. Similar results have been found
in other studies in patients with pain, where rates of
completion were signiﬁcantly better for the EQ-5D over
the course of an RCT in patients with non-speciﬁc neck
pain27 and in patients with low back pain and degenera-
tive disease.25 Finally, it should be noted that a new
5-level version of the EQ-5D has recently been
launched31 and its application in patients with various
chronic conditions (eg, osteoarthritis) suggests it might
have improved discriminative capacity and sensitivity to
change than the EQ-5D 3-level version.32 The use of
both the EQ-5D and the SF-6D might be the best
approach in future trials in patients with chronic pain.
In conclusion, the present study suggests that
pharmacist-led medication review with or without pre-
scribing in patients with chronic pain in primary care
had similar effects in terms of QALYs compared with
treatment as usual but was more expensive. These results,
however, are highly uncertain due to the small sample
size of the pilot trial and do not reﬂect the previously
reported signiﬁcantly improved chronic pain grade. The
EVSI analysis indicated that this current evidence is insuf-
ﬁcient for decision-making and that a future larger trial is
worthwhile. Such a trial would require between 460 and
690 patients and between 540 and 780 patients per arm
using a threshold of £30 000 and £20 000 per QALY
gained, respectively, in order to obtain more precise esti-
mates of differences in mean effects (QALYs) and mean
costs between treatment groups.
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Table 4 EVSI sensitivity analyses*
WTP of £20 000 per QALY gained WTP of £30 000 per QALY gained
Prescribing vs TAU Review vs TAU Prescribing vs TAU Review vs TAU
Base case 780 540 690 460
Annual incidence halved 780 540 690 460
Annual incidence doubled 780 540 690 460
Recruitment cost halved 780 540 690 460
Recruitment cost doubled 780 540 690 460
Annual accrual rate halved 550 370 320 320
Annual accrual rate doubled 1110 770 670 670
Time horizon 10 years 300 300 250 250
Time horizon 20 years 440 430 370 370
*Estimates rounded to the nearest 10.
EVSI, expected value of sample information; TAU, treatment as usual; WTP, willingness to pay.
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